CD8A and neoplasm: Despite the absence of mRBC-240 in tumors, expansion and activation of NK cells and CD8 + T cells was observed in both the spleen and the tumor in mRBC-240-treated mice, suggesting that these immune cells are activated by mRBC-240 in the spleen and then traffic to the tumor.